Brief: Xencor, MD Anderson Enter Strategic Collaboration To Develop Novel T Cell-Engaging Bispecific Antibodies
06/01/2021 21:21
Jan 6 (Reuters) - Xencor Inc XNCR.O :
* XENCOR AND MD ANDERSON ENTER STRATEGIC COLLABORATION TO
DEVELOP
NOVEL T CELL-ENGAGING BISPECIFIC ANTIBODIES FOR POTENTIAL
TREATMENT OF PATIENTS WITH CANCER
Source text for Eikon: ID:nBw7Pvwb2a
Further company coverage: XNCR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Xencor
See all newsXencor, Inc. reports results for the quarter ended June 30 - Earnings Summary
Biopharma firm Xencor's Q2 revenue beats on royalty revenue, milestone payments
Brief: Xencor Q2 EPS USD -0.29
Brief: Xencor To Receive $105 Million From Alexion To Resolve Ultomiris® U.S. Royalty Matter
Xencor Q1 revenue falls sharply and misses estimates